GARP Research Reaffirms Buy Rating on Luminex (LMNX)
Shares of Luminex traded down 2.19% during mid-day trading on Wednesday, hitting $24.15. Luminex has a 52 week low of $18.33 and a 52 week high of $25.16. The company has a market cap of $1.009 billion and a P/E ratio of 72.62.
The company last announced its quarterly results on Monday, April 30th. It reported $0.08 earnings per share (EPS) for the previous quarter, missing the Thomson Reuters consensus estimate of $0.09 EPS by $0.01. The company’s quarterly revenue was up 12.5% on a year-over-year basis. On average, analysts predict that Luminex will post $0.12 earnings per share next quarter.
LMNX has been the subject of a number of other recent research reports. Analysts at UBS AG (NYSE: UBS) raised their price target on shares of Luminex from $22.00 to $25.00 in a research note to investors on Tuesday. They now have a “neutral” rating on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Luminex in a research note to investors on Wednesday, February 8th. They now have a $22.00 price target on the stock.
Luminex Corporation (Luminex) develops, manufactures and sells biological testing technologies and products with applications throughout the life sciences and diagnostics industries.